Anti-Mouse IL-1b Antibody (B122) is a monoclonal antibody inhibitor targeting mouse IL-1β. It blocks IL-1β signaling, thereby reducing monocyte infiltration and alleviating T cell exhaustion, making it useful for studying cancer and cardiovascular diseases. When combined with sulfasalazine, Anti-Mouse IL-1β Antibody (B122) enhances ferroptosis and reactive oxygen species (ROS) levels.

Anti-Mouse IL-1b Antibody (B122) (50 pM, 6-72 hours) combined with Sulfasalazine significantly inhibits the proliferative activity of tumor cells such as SCC1, A375, and MDA-MB231 [1].
Anti-Mouse IL-1b Antibody (B122) (50 pM, 24 hours) combined with Sulfasalazine downregulates the expression level of intracellular IL-1β while enhancing the expression of ferroptosis-related markers [1].
Anti-Mouse IL-1b Antibody (B122) (50 pM, 24 hours) combined with Sulfasalazine increases the level of reactive oxygen species in SCC1 cells while reducing the level of glutathione [1].

Anti-Mouse IL-1b Antibody (B122) (100 μg/kg, intratumoral injection, once every 3 days for 4 weeks) combined with Sulfasalazine treatment in male SD rats with oral squamous cell carcinoma (OSCC) can significantly inhibit tumor progression [1].
Anti-Mouse IL-1b Antibody (B122) (1 mg, intratumoral injection, once daily until endpoint) significantly prolongs the survival time of Ntv-a mice with PDGFB overexpression and p53 silencing [2].
Anti-Mouse IL-1b Antibody (B122) (100 μg, intraperitoneal injection, twice weekly for 2 weeks) can preserve right ventricular function and pulmonary vascular remodeling capacity in HFpEF C57BL/6J mice [3].

B122

Mouse

Monoclonal

Unconjugated